Invariant Investment Management Invests $1.11 Million in McKesson Corporation $MCK

Key Points

• Invariant Investment Management bought a new position of 1,358 McKesson shares in Q4 valued at about $1.11 million, representing roughly 0.7% of its holdings and the stock's 17th largest position.
• McKesson beat Q4 expectations, reporting $9.34 EPS versus $9.19 expected and $106.16 billion in revenue (+11.4% YoY), and set FY2026 guidance of $38.80–$39.20 EPS.
• The company recently paid a quarterly dividend of $0.82 (annualized $3.28, yield 0.4%), while insiders sold about 3,592 shares (~$3.52M) in the last three months and institutional investors own ~85.07% of the stock.

Invariant Investment Management purchased a new position in shares of McKesson Corporation (NYSE:MCK - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,358 shares of the company's stock, valued at approximately $1,108,000. McKesson comprises about 0.7% of Invariant Investment Management's holdings, making the stock its 17th largest holding.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GGM Financials LLC acquired a new stake in shares of McKesson during the 3rd quarter worth approximately $25,000. State of Wyoming acquired a new stake in shares of McKesson during the 2nd quarter worth approximately $29,000. Hopwood Financial Services Inc. purchased a new position in shares of McKesson during the 3rd quarter worth approximately $31,000. Vermillion & White Wealth Management Group LLC purchased a new position in shares of McKesson during the 3rd quarter worth approximately $33,000. Finally, Board of the Pension Protection Fund purchased a new position in shares of McKesson during the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 85.07% of the company's stock.

McKesson Stock Down 0.2%

Shares of MCK stock opened at $862.77 on Wednesday. McKesson Corporation has a 52 week low of $637.00 and a 52 week high of $999.00. The stock has a market capitalization of $105.68 billion, a PE ratio of 24.81, a P/E/G ratio of 1.25 and a beta of 0.42. The firm has a 50 day moving average of $916.80 and a two-hundred day moving average of $853.48.

McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating the consensus estimate of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The company had revenue of $106.16 billion during the quarter, compared to analysts' expectations of $105.98 billion. During the same quarter last year, the company posted $8.03 EPS. The firm's revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Analysts expect that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 1st. Investors of record on Monday, March 2nd were paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date was Monday, March 2nd. McKesson's dividend payout ratio is presently 9.43%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Mizuho increased their price objective on shares of McKesson from $880.00 to $885.00 and gave the stock a "neutral" rating in a research report on Thursday, February 5th. Wells Fargo & Company increased their price objective on shares of McKesson from $914.00 to $925.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 5th. Robert W. Baird set a $968.00 price objective on shares of McKesson in a research report on Wednesday, January 14th. Weiss Ratings cut shares of McKesson from a "buy (a-)" rating to a "buy (b+)" rating in a research report on Thursday, February 5th. Finally, Leerink Partners reaffirmed an "outperform" rating and set a $1,085.00 price objective on shares of McKesson in a research report on Thursday, March 5th. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $970.93.

Insider Activity

In other news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of McKesson stock in a transaction on Friday, February 6th. The shares were sold at an average price of $955.00, for a total transaction of $313,240.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the sale, the executive vice president directly owned 2,989 shares of the company's stock, valued at approximately $2,824,605. This trade represents a 5.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,592 shares of company stock valued at $3,518,555 over the last three months. 0.08% of the stock is currently owned by corporate insiders.

About McKesson

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.